000130144 001__ 130144
000130144 005__ 20241125101153.0
000130144 0247_ $$2doi$$a10.3390/nu15183983
000130144 0248_ $$2sideral$$a136453
000130144 037__ $$aART-2023-136453
000130144 041__ $$aeng
000130144 100__ $$aGarcía-Mateo, Sandra$$uUniversidad de Zaragoza
000130144 245__ $$aLifestyle can exert a significant impact on the development of metabolic complications and quality life in patients with inflammatory bowel disease
000130144 260__ $$c2023
000130144 5060_ $$aAccess copy available to the general public$$fUnrestricted
000130144 5203_ $$aInflammatory bowel diseases (IBDs) are associated with an increased risk of metabolic comorbidities. There is a lack of data regarding the relationship between lifestyle and metabolic diseases in IBD patients. A cross-sectional study on consecutive IBD outpatients was conducted. Adherence to the Mediterranean diet (MD) was assessed using a 14-item questionnaire from the PREDIMED study, and physical activity was evaluated using the GODIN-Leisure score. Body composition was studied based on body mass index and waist–hip ratio (WHR), while quality of life was assessed using a nine-item short questionnaire. Among the 688 evaluated IBD patients, 66% were overweight or obese, 72.7% did not lead an active lifestyle and 70.1% did not adhere to the MD. Metabolic syndrome was associated with age (OR = 1.07, p = 0.019), overweight/obesity (OR = 12.987, p < 0.001) and the inflammatory behavior of Crohn’s disease (OR = 6.172, p = 0.001). Type 2 diabetes mellitus or prediabetes was associated with age (OR = 1.063 p = 0.016), overweight/obesity (OR = 3.861, p < 0.001) and the inflammatory behavior of Crohn’s disease (OR = 4.716, p = 0.001). Overweight /obesity (OR = 5.494, p < 0.001), a high WHR (OR = 2.564, p = 0.005) and a non-active lifestyle (OR = 2.202, p = 0.0003) were associated with metabolic dysfunction-associated steatotic liver disease. Lifestyle, body composition and not solely systemic inflammation might exert a significant influence on the emergence of metabolic comorbidities such as MASLD, type 2 diabetes mellitus and metabolic syndrome in patients with IBD.
000130144 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000130144 590__ $$a4.8$$b2023
000130144 592__ $$a1.301$$b2023
000130144 591__ $$aNUTRITION & DIETETICS$$b18 / 114 = 0.158$$c2023$$dQ1$$eT1
000130144 593__ $$aNutrition and Dietetics$$c2023$$dQ1
000130144 593__ $$aFood Science$$c2023$$dQ1
000130144 594__ $$a9.2$$b2023
000130144 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000130144 700__ $$aMartínez-Domínguez, Samuel J.$$uUniversidad de Zaragoza
000130144 700__ $$0(orcid)0000-0002-3545-2707$$aGargallo-Puyuelo, Carla Jerusalén$$uUniversidad de Zaragoza
000130144 700__ $$0(orcid)0000-0002-4991-8715$$aArroyo Villarino, María Teresa$$uUniversidad de Zaragoza
000130144 700__ $$aLaredo De La Torre, Viviana
000130144 700__ $$aGallego, Beatriz
000130144 700__ $$aAlfambra, Erika
000130144 700__ $$0(orcid)0000-0003-0076-3529$$aGomollón, Fernando$$uUniversidad de Zaragoza
000130144 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000130144 773__ $$g15, 18 (2023), 3983 [14 pp.]$$pNutrients$$tNutrients$$x2072-6643
000130144 8564_ $$s830486$$uhttps://zaguan.unizar.es/record/130144/files/texto_completo.pdf$$yVersión publicada
000130144 8564_ $$s2639045$$uhttps://zaguan.unizar.es/record/130144/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000130144 909CO $$ooai:zaguan.unizar.es:130144$$particulos$$pdriver
000130144 951__ $$a2024-11-22-12:08:04
000130144 980__ $$aARTICLE